摘要
冠心病、房颤是临床心血管疾病的常见病,其心衰、心律失常、缺血性卒中等并发症的高致残率、致死率严重危害着患者的生活质量和生命安全,而抗栓药物(包括抗血小板和抗凝药物)在冠心病、房颤及冠脉介入治疗用药中扮演了举足轻重、不可比拟的角色。为进一步控制出血风险,提高高危缺血风险患者的强化抗栓疗效,近几年来不断研发推出了新的抗栓药物,结合近期各大临床指南的一致更新推荐,将使患者在临床治疗中真正获益。
Coronary heart disease and atrial fibrillation are the most common cardiovascular diseases, whose complications, such as heart failure, arrhythmia and ischemic stroke, result in high mortality and disability rates. Antithrombotic agents, including antiplatelet and anticoagulant agents, play an unparalleled important role in the interventional treatment of coronary heart disease and atrial fibrillation. To further control the bleeding risk and benefit more from more intensified antithrombotic efficacy in patients of high ischemic risks, new antithrombotic agents of choice with their evidence-based indications have been unremittingly analyzed and evaluated in recent years, some of which have already obtained consistent recommendations from the updates of major clinical guidelines, and may bene- fit more patients.
出处
《海南医学》
CAS
2012年第24期125-132,共8页
Hainan Medical Journal
关键词
抗血小板药物
抗凝药物
冠心病
房颤
指南
Antiplatelet drugs
Antieoagulation drugs
Coronary heart disease
Atrial fibrillation
Guideline
